AC Immune (ACIU) Retained Earnings (2015 - 2026)
AC Immune (ACIU) posted quarterly Retained Earnings of -$578.3 billion for Q1 2026, down 134524.84% year-over-year from N/an in Q1 2025, and down 5.28% quarter-over-quarter from -$549.3 billion in Q4 2025.
AC Immune (ACIU) Retained Earnings (2015 - 2026) Analysis & Trends
AC Immune (ACIU) has reported Retained Earnings for 12 consecutive years, with -$578.3 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Retained Earnings fell 134524.84% year-over-year to -$578.3 billion; the TTM figure through Mar 2026 stood at -$578.3 billion (down 134524.84% YoY), while the FY2025 annual figure was -$529.5 billion, down 125869.34% from the prior year.
- Retained Earnings slipped to -$578.3 billion in Q1 2026 per ACIU's latest filing, from -$549.3 billion in the prior quarter.
- Across five years, Retained Earnings topped out at -$251.6 million in Q3 2022 and bottomed at -$578.3 billion in Q1 2026.
- Historically, Retained Earnings has averaged -$115.6 billion across 5 years, with a median of -$420.4 million in 2024.
- Annual changes were most pronounced in 2024 — Retained Earnings soared 99.88% — and 2026, when it plunged 134524.84%.
- AC Immune's Retained Earnings stood at -$274.1 million in 2022, then sank by 129971.79% to -$356.5 billion in 2023, then jumped by 99.88% to -$420.4 million in 2024, then tumbled by 130573.5% to -$549.3 billion in 2025, then decreased by 5.28% to -$578.3 billion in 2026.
- Business Quant data shows ACIU's Retained Earnings at -$578.3 billion in Q1 2026, -$549.3 billion in Q4 2025, and -$524.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | AC Immune | 253.89 Mn | 253.89 Mn | - | -569.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -569.91 Mn |
| Mar 31, 2026 | -578.30 Bn |
| Dec 31, 2025 | -549.29 Bn |
| Sep 30, 2025 | -524.73 Mn |
| Jun 30, 2025 | -491.56 Mn |
| Mar 31, 2025 | -429.56 Mn |
| Dec 31, 2024 | -420.35 Mn |
| Sep 30, 2024 | -402.75 Mn |
| Jun 30, 2024 | -392.12 Mn |
| Mar 31, 2024 | -381.01 Mn |
| Dec 31, 2023 | -356.47 Bn |
| Sep 30, 2023 | -351.52 Mn |
| Jun 30, 2023 | -329.27 Mn |
| Mar 31, 2023 | -302.84 Mn |
| Dec 31, 2022 | -274.05 Mn |
| Sep 30, 2022 | -251.61 Mn |
| Jun 30, 2022 | -238.98 Bn |
| Mar 31, 2022 | -236.91 Bn |
| Dec 31, 2021 | -217.92 Bn |
| Sep 30, 2021 | -197.86 Bn |